Current Trials on MDRO Containment

Susan S. Huang, MD MPH Assistant Professor and Hospital Epidemiologist Division of Infectious Diseases Health Policy Research Institute University of California Irvine School of Medicine

Disclosures: None

Strategies to Reduce MDROs

Majority of efforts directed at MRSA/VRE

- Vaccinate
- Contact precautions
- Active screening
- Enhanced cleaning
- Decolonization
- Antibiotic rotation

Vaccination Trials

S. aureus conjugate vaccine

 Capsular polysaccharides 5 and 8

 Tested on 1,804 patients on hemodialysis
 Robust early antibody response

Shinefield H et al. New Engl J Med 2002; 346:491-96

 TABLE 4. GEOMETRIC MEAN LEVELS OF ANTIBODIES SPECIFIC

 FOR STAPHYLOCOCCUS AUREUS TYPE 5 AND 8 CAPSULAR

 POLYSACCHARIDES.*

TIME OF EVALUATION	VACCINE GR	PLACEBO GROUP			
	NO. OF PATIENTS TYPE 5	TYPE 8	NO. OF PATIENTS	TYPE 5	TYPE 8
	μ g/ml			μ g/ml	
Before injection	892 5.9	8.6	910	5.7	8.6
Week 6	884 230.0	206.0	900	5.6	8.6
Week 26	838 120.0	100.0	859	5.8	8.9
Week 54	763 74.2	64.5	776	5.7	8.9
Week 67	507 78.1	65.8	512	6.2	9.4

TABLE 2. CUMULATIVE NUMBER OF PATIENTS IN WHOM

 STAPHYLOCOCCUS AUREUS BACTEREMIA DEVELOPED AND EFFICACY

 OF THE VACCINE.*

Weeks After Injection		GROUP	PLACEBO	GROUP	Efficacy (95% CI)	P Value
	NO.	PERSON-	NO.	PERSON-		
	INFECTED	YEARS	INFECTED	YEARS		
					%	
10	4	135.2	5	138.0	18 (-28 to 84)	1.0
20	6	300.6	13	306.6	53 (-33 to 85)	0.17
30	8	461.9	22	469.7	63 (14 to 86)	0.02
40	11	618.9	26	627.0	57 (10 to 81)	0.02
50	25	766.5	34	775.3	26 (-28 to 58)	0.30
54	27	818.4	37	827.4	26 (-24 to 57)	0.23
91	37	1165.0	49	1161.6	25 (-18 to 52)	0.24

Provided partial immunity

- Initially thought to be protective till 40 weeks
- Failed to verify effect with serial inoculations
- ->3,500 person trial Phase III failed

Shinefield et al. *New Engl J Med* 2002; 346:491-96 Fattom et al. Vaccine 2004;23(5):656-63

Vaccines in Clinical Trials

Candidate	Sponsor	Rationale	Status
StaphVAX	Nabi Biopharmaceuticals	CP5, CP8	Phase III failed
Veronate	Inhibitex	Cell Wall Adhesins	Phase III failed
v710	Merck	Monovalent ?Iron Surface Determinant B?	Phase III clinical trials
SA3Ag	Pfizer/Wyeth	Tri-valent CP5, CP8, rClfAm	Phase I Early 2011
Pentastaph	GSK (Nabi)	CP5, CP8, cell wall antigen 336, PVL and α toxin	Phase 1 3 of 4 milestones already met

Value

Prevent infection among carriers

 Reducing carriage
 Reducing acquisition

 Moderate efficacy highly valuable
 Potential long term benefit

Strategies to Reduce MDROs

Vaccinate Contact precautions Active screening Enhanced cleaning Decolonization Antibiotic rotation

Contact Precautions

Common Guidelines

Contact Precautions

 Hand hygiene to enter
 Gown and glove to enter room/contact

 Cohorting

 Single room or
 Rooming with other MDRO patients

Contact Precautions

- Dozens of studies
- Successful response to outbreak conditions
- Successful response to endemic MDROs
- All observational
- Overall, precautions favored, but studies not definitive

Cooper et al. Health Technology Assessment 2003;7(39):1-194

Contact Precautions

- Widely used and internationally recommended
- Logical benefit
- Final answer unknown
 - Isolated effect difficult to study
 - Quantitative effect difficult to study
 - Time window to randomize may have passed
 - Research focus is now on other interventions

Universal Glove & Gowning Study

- Recruiting (US)
- Cluster randomized trial of 18+ ICUs
- Arm 1: Routine contact precautions
- Arm 2: Universal contact precautions
- Study Period: Apr 2011 Mar 2012
- Outcomes
 - MRSA, VRE ICU acquisition
 - ICU associated infection rates

AHRQ funded, Task Order PI: Anthony Harris , ACTION network (Yale)

Strategies to Reduce MDROs


Vaccinate Contact precautions Active screening Enhanced cleaning Decolonization Antibiotic rotation

Active Screening & Isolation

The Iceberg Phenomenon



The Iceberg Phenomenon




Value of Active Surveillance

Knowledge of iceberg


- Increases detection
- Increases awareness
- Corrects misclassification
- Rapid isolation
 - Contact precautions
 - Prevents transmission

ICU Screening & Isolation Impact on MRSA Bacteremia




Huang SS et al. Clin Infect Dis. 2006:43;971-8

Phased In Screening & Isolation Impact on MRSA Acquisition




VA Pittsburgh Medical Center Ellingson et al. SHEA 2008

Housewide Screening & Isolation Impact on MRSA Infections



Evanston Northwestern Health Care Robicsek et al. Ann Int Med 2008;148:409-18


High Risk Screening & Isolation Impact on MRSA Infection



Klinikum im Fredrichshain, Berlin Germany Wernitz et al. Clin Microbiol Infect 2005:11;457-65

Trends in MRSA Paris 1993 - 2006

MRSA Prevalence among *S.aureus* clinical samples



STAR ICU Trial

Strategies to reduce Transmission of Antimicrobial Resistant bacteria in ICUs

- Cluster RCT evaluating intensive precaution measures to prevent MDROs (C Huskins, USA)
- Two ICU Arms
 - Universal gloving, plus screen and isolate
 - Routine care (but screen without results)

NIH funded; Clinicaltrials.gov

STAR ICU Trial

Sample Size
 19 hospitals, 15 US states

Study Period 2005-6

Outcome

Incidence of MRSA and VRE acquisition MRSA and VRE bacteremia

STAR ICU Trial

Major trial design flaw

- All screens sent to central laboratory (CDC)
- Screening results returned on average 2 days longer than average LOS in ICU
- Effectively a study of universal gloving

Outcome

- No substantial benefit (prelim report)
- Final publication forthcoming (NEJM)

MOSAR Trials Mastering hOSpital Antibiotic Resistance

- European consortium
- Three trials
 - Intensive Care Units (M Bonten, UMCU, NL)
 - Surgical Care Units (S Harbarth, UNIGE, CH)
 - Rehabilitation Centers (Y Carmeli, TASMC, IL)
- Evaluation of acquisition of MDROs

MOSAR Trials Mastering hOSpital Antibiotic Resistance

The Intensive Care Unit Trial

- Objective
 - Compare incremental effects of:
 Enhancing basic infection control measures
 Active surveillance by culture + isolation
 Active surveillance by PCR + isolation

Outcomes

- ICU associated acquisition MRSA, VRE, ESBL
- ICU-associated MRSA, VRE, ESBL bacteremia
- ICU stay, hospital stay, mortality

MOSAR Trials: The Intensive Care Units Trial

- 13 adult ICUs
- Cluster Randomized
- Launch: May 2008
- Phase 1: Baseline (6 mo)
- Phase 2: (All sites, 6 mo)
 - Hand hygiene campaign
 - Daily CHG bathing



- Phase 3 (12 mo), randomized for active surveillance
 - Arm 1: Chromagar for MRSA/VRE; no active ESBL detection
 - Arm 2: PCR for MRSA/VRE; chromagar for ESBL

MOSAR Trials: The Intensive Care Units Trial

Data collection will complete March 2011

- >11,000 patients, >110,000 patient days
- Final analyses: Early 2012
- Critical value
 - Value of screening over universal CHG bathing
 - Value of PCR over conventional screening

MOSAR Trials Mastering hOSpital Antibiotic Resistance

- The Surgical Units Trial
- Objective
 - Compare basic infection control measures vs active screening and isolation in non-ICU surgical wards




Options to Reduce MDROs

Vaccinate
Contact precautions
Active screening
Enhanced cleaning
Decolonization
Antibiotic rotation

Enhanced Cleaning

Bacteria on a Pen Tip



PRIMO Trial

PRevention of Infection caused by Methicillin or Oxacillin resistant *S. aureus*

RCT to Prevent Recurrent CA-MRSA Infection
 2x2 Clinical Trial (L Miller, Harbor UCLA, USA)

- No intervention
- Household cleaning intervention (topical ETOH)
- Decolonization (7d mupirocin, 14d CHG bathing)
- Household cleaning + Decolonization

NIH- funded; Clinicaltrials.gov: NCT00560599

PRIMO Trial Decolonization vs Cleaning

Sample Size
 350 households with recent CA-MRSA infection

Outcome MRSA infection within 52 weeks

Study Period
 2007-2010, completed, analysis pending

Options to Reduce MDROs

Vaccinate
Contact precautions
Active screening
Enhanced cleaning
Decolonization
Antibiotic rotation

Decolonize

Value of Decolonization

Benefits prevalent cases

- Infection risk in known carriers
 - 1 in 3 in critically and chronically ill
 - 1 in 9 among nursing home residents
- Most common regimen for MRSA
 - Mupirocin for nasal reservoir
 - Chlorhexidine for skin decontamination
 - Avoids resistance to treatment agents

Mupirocin

Short-term mupirocin highly effective ¹
 90% elimination of MRSA at 1 week
 60% prolonged elimination

1%-7%² resistance over time

¹ Ammeriaan HS et al. Clin Infect Dis 2009;48(7):922-30
 ² Robicsek A et al. Infect Control Hosp Epidemiol 2009;30(7):623-32

Chlorhexidine

- Topical cleansing agent, over the counter
- Used in healthcare for >50 years
- Marked reduction in skin/room bacteria
- Commonly used for
 - MRSA decolonization
 - Pre-operative bathing/showering
 - Skin prep before central lines/operations

Chlorhexidine and Bacteremia





Figure 2. Kaplan-Meier survival curve for occurrence of bloodstream infection (BSI) by study arm. CHG indicates chlorhexidine gluconate; MICU, medical intensive care unit.


Bleasdale et al. Arch Intern Med 2007;167(19):2073-9

Multi-Center ICU Study of CHG



Climo M et al. Crit Care 2009;37(6):1858-65

Risk Ratios for Skin Contamination and Environmental or Health Care Worker Contamination by or Patient Acquisition of VRE



Vernon et al, Arch Intern Med 2006; 166:306-12.

ARCHIVES OF INTERNAL MEDICINE

The REDUCE MRSA Trial

A multi-center cluster randomized study

AHRQ funded; Clinicaltrials.gov NCT00980980

REDUCE MRSA

Randomized Evaluation of Decolonization vs. Universal Clearance to Eliminate MRSA

Susan Huang, MD MPH Richard Platt, Ed Septimus, John Jernigan, Jason Hickok, Julia Moody, Jonathan Perlin for the REDUCE MRSA Working Group

CDC Prevention Epicenters Harvard Pilgrim Health Care Hospital Corporation of America



The REDUCE MRSA Trial

3-Way Cluster Randomized Trial (US)

- Randomizes whole hospitals (all adult ICUs)
- 42 hospital participants/74 ICUs
- 16 states
- Arm 1: Routine Care
 - Screen and isolate only
- Arm 2: Targeted Decolonization
 - Screen, isolate, and decolonize if MRSA+
- Arm 3: Universal Decolonization
 - Stop screening, isolate known MRSA+, decolonize all

REDUCE MRSA Trial Outcomes

Main Outcome

 Any clinical MRSA isolate attributed to an ICU or post-ICU (cultures attributed to unit 2d prior)

Secondary Outcomes

- (ICU, post-ICU, and hospital-wide analyses)
 - Blood and urine MRSA infections
 - Blood and urine infections, all pathogens
 - Antibiotic resistance to mupirocin or chlorhexidine

Trial Status and Timeline

Trial duration April 1, 2010 – Sept 30, 2011

>95% compliance in all facilities, every arm

Final results expected in 2012



CHANGING LIVES BY ERADICATING ANTIBIOTIC RESISTANCE

A randomized clinical trial Southern California, USA

AHRQ funded; Clinicaltrials.gov NCT00980980

Project CLEAR

RCT to prevent MRSA infections among carriers in the year following discharge

- Arm 1: Standard of Care Hygiene Education
- Arm 2: Education + Decolonization

5 days application twice a month for 6 months

- Mupirocin to bilateral nares
- Chlorhexidine bathing
- Chlorhexidine mouthwash

Project CLEAR

- Sample Size
 - **1700**
- Follow up
 - 1 year
 - 4 clinic visits with serial cultures
- Medical records requested for
 - All hospitalizations
 - Any clinic visit for possible infection

Project CLEAR Recruitment

Recruitment

Adults at discharge from hospitals or admission to nursing homes in Southern California (Orange County and Southern Los Angeles)

Outcomes

MRSA infection, rehospitalization 1 yr post-discharge Increased mupirocin or chlorhexidine resistance

Study Period Jan 2011-Mid 2013

Options to Reduce MDROs

Vaccinate
Contact precautions
Active screening
Enhanced cleaning
Decolonization
Antibiotic rotation

SATURN ICU Trial

Impact of Specific Antibiotic Therapies on the prevalence of hUman host ResistaNt bacteria

Randomized cross over trial

Arm 1: Fast rotation

- Every other patient rotates antibiotics
- cephalosporins, pip-tazo, carbapenems

Arm 2: Slow rotation

Every 1.5 months, unit rotates antibiotic

Clinicaltrial.gov: NCT01293071

SATURN ICU Trial

Primary Outcome

Prevalence of antibiotic resistant GNR

Secondary Outcome

- Acquisition of antibiotic resistant GNR
- Antibiotic resistant GNR bacteremia

Study Period

- Spring 2011 - Jan 2013

Conclusions

MDROs are a national priority

Increasing carriage and disease prevalence

Need answers for containment

- Staph vaccine trials
- Universal Gown & Gloving Trial
- MOSAR Trials
- PRIMO Study
- REDUCE MRSA Trial
- Project CLEAR
- SATURN

Questions?

